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The didemnins represent a versatile class of depsipeptides of marine origin and hold a great deal
of potential for biomedical application. The biological and geographical origins of the didemnins are
reviewed in addition to the chemical structures of the major didemnins. The biological mechanisms
behind the antiviral and anticancer effects of selected didemnins are summarized and the special
case of dehydrodidemnin B (AplidinTM ) is expounded upon including structural characteristics,
synthesis, pharmacological mechanism and a discussion of its current clinical trials as an anticancer
agent.
I. INTRODUCTION
The didemnins represent a versatile class of depsipep-
tides of marine origin and as such they are true natural
products. While their discovery and structural elucida-
tion has been challenging to the researchers involved, the
didemnins hold a great deal of potential in pharmacolog-
ical application.
Since their first isolation from Trididemnum solidum
20 years ago, natural product chemists have struggled
to determine their structure, origin and biosynthesis.
And while a great deal of knowledge has been gained,
the didemnins still remain a mysterious natural product,
making this class of cyclic peptides a fascinating subject
of chemical research.
The cytotoxic nature of the didemnins was identified
immediately upon cell culture screening. Since their
discovery1 they have found applications as antibiotic, an-
tiviral and anticancer agents. The relatively high degree
of specificity for their action, combined with newly devel-
oped methods of high-yield synthesis, have made them
a perfect candidate class of compounds to explore for
drug discovery. And there are infact several didemnins
currently undergoing clinical trials as anticancer agents,
the most successful of which thus far has been dehydro-
didemnin B (AplidinTM ), a subject that is discussed in
this review.
II. BIOLOGICAL AND GEOGRAPHICAL
ORIGINS OF THE DIDEMNIN FAMILY OF
NATURAL PRODUCTS
Many of the didemnins known have been isolated
from the Caribbean tunicate Trididemnum solidum. Tri-
didemnun belong to the suborder Aplousobranchia, or-
der Enterogona, class Ascidiacea, subphylum Urochor-
data, phylum Chordata. These tunicates (also known
as sea squirts) are found in the warm Caribbean waters
and have been located in Belize, Columbia, Mexico, Hon-
duras, Panama and Brazil1,2. It has been noted that the
class Ascidiacea contains the only urochordatans that
have yielded natural products to date3. However, this
may merely be due to lack of specimen collection and it
is equally possible that natural products will be found in
the other classes of Urochordata; the fact that Ascidiacea
is the largest of the classes may also play a role in this
over-representation3.
An interesting case is that of dehydrodidemnin B,
which was isolated unexpectedly from the Mediterranean
tunicate Alpidium albicans4. The strong relationship be-
tween dehydrodidemnin and the other didemnins isolated
from the Caribbean tunicates is intriguing given the ge-
ographical distance between species.
The ascidiates are typically solitary creatures that re-
main anchored on the sea floor and may be sparingly
motile. They draw in seawater around them, filter it
through mucosal membranes to catch nutrients, and then
expel the water back along with any waste products.
Didemnums and Tridemnums are unique in that they
may fuse to form clusters of more than one individual
organism and may form a single inlet chamber to draw
in the surrounding water5.
It is unclear whether the origin of the didemnin nat-
ural products is ascidian, algal or prokaryotic in nature.
As is frequently the case in marine natural products,
determining the exact organism responsible for the sec-
ondary metabolites can be exceptionally difficult due to
the symbiotic relationships that exist naturally, and also
in part due to the ecological interplay between species
chemically. For example, ascidians are known to house
prokaryotes such as Synechocystis and Prochloron, and
there are almost certainly other symbionts whose distinct
identity has not yet been determined3.
III. STRUCTURAL CHARACTERISTICS
The signature characteristic of the didemnins is the
depsipeptide macrocycle skeleton. This depsipeptide cy-
cle is composed of tyrosine-proline-leucine linked to an
α-(α-hydroxyisovaleryl)propionyl (Hip) group which in
turn is connected to an isostatine unit by an ester bond;
on the amide-side of isostatine is a threonine whose hy-
2FIG. 1: The standard Hip/Isostatine macrocycle template
for the didemnin family of natural products. Other varia-
tions include norstatine and hydroxyisovaleric acid (Hiv). The
methylated Tyr and Leu residues would appear to indicate
enzymatic ”tailoring” of the macrocycle.
droxyl side group is ester-linked back to the starting
methyl-modified tyrosine, thereby closing the depsipep-
tide ring. The N-terminal side of the threonine forms
a peptide bond with a methyl-modified leucine; inter-
estingly, this leucine is the D-leucine enantiomer, as op-
posed to the amino acids of the macrocycle which are
all L isomers as typically found in biosynthetic peptides;
figure 1 depicts the basic macrocycle for the majority of
the didemnins (and as explained below, the Hip and iso-
statine groups may vary depending upon the subtype of
didemnin).
Historically, determining the macrocycle structure
proved to be challenging. Initial studies of the
didemnin structure were conducted by NMR and chem-
ical methods6, gas chromatography7 and the structure
and isomerism of the didemnin family was revised sev-
eral times; one of the greatest impediments is that it was
originally believed the isostatine member of the didemnin
B macrocycle was actually a statine until X-ray crystal-
lography studies demonstrated otherwise8. The stereo-
chemistry of the Hip group also proved to be a challenge
to determine, and it was nearly 10 years before the struc-
ture of the macrocycle had been confidently settled9.
Past the N-methylated D-leucine lies a variable side-
chain that identifies the different didemnins (see figure
2 below for a summary of the side-chains from some of
the didemnins). Didemnin A, considered to be a struc-
tural parent of other derivatives (in terms of it’s sim-
plicity and also as a synthetic precursor), has simply a
proton for it’s side-chain. The side-chain of didemnin B
is a proline-lactic acid residue proper (which in itself is
a common side-chain starting point for the majority of
the known didemnins); a class of didemnins known as
the tamandarins also have this side-chain, however they
have a Hiv (hydroxyisovaleric acid) rather than a Hip
in the macrocycle2. In the case of both tamandarin B
Didemnin A R = H
Didemnin B R = L-Pro-L-Lac
Didemnin C R = L-Lac
Didemnin D R = L-Pro-L-Lac-(L-Gln)3-L-pGlu
Didemnin E R = L-Pro-L-Lac-(L-Gln)2-L-pGlu
Didemnin G R = CHO
Didemnin M R = L-Pro-L-Lac-L-Gln-L-pGlu
Didemnin X R = L-Pro-L-Lac-(L-Gln)3-Hydec
Didemnin Y R = L-Pro-L-Lac-(L-Gln)4-Hydec
Dehydrodidemnin B R = L-Pro-Pyruvate
FIG. 2: R groups that follow the N-Me-D-Leu sidearm for
some of the various didemnins that have been discovered to
date. This list is not exhaustive, as there have been more
than 40 didemnins discovered and/or synthesized.
and nordidemnin B the isostatine has been replaced by
a norstatine (norstatine is identical to isostatine except
that it lacks a methyl, giving it an isopropyl rather than
an isobutyl side-group)10.
Didemnins D, E and M are interesting in that their
side-chains contain varying lengths of pyroglutamic acid
and glutamine following the proline-lactic acid motif11.
Also described by Rinehart in a patent are didemnins X
and Y, which are similar to D, E and M but they end
the side-chain with a Hydec (hydroxydecanoic acid), a
10-carbon carboxylic acid.
How could such a unique class of compounds be biosyn-
thesized? The question is especially intriguing in light of
the macrocycle: is the cyclic peptide simply made by
ribosomal translation (which would imply a small RNA
source template), or could the fragments originate from
another cellular source, such as the proteasome, and then
the peptide bonds formed by some other enzyme? If it
is formed by mRNA/protein translation, how does one
explain the Hip/Hiv and isostatine, or norstatine inte-
gral units? And if the source of the peptide fragments
were proteasomal in nature, then would this allow for
didemnins to be made in a recombinatorial manner, in
response to some event where a foreign protein was de-
graded? The presence of the leucine (a D-Leucine iso-
mer no less - highly unusual in living systems) on the
side-chain of all the known didemnins would also sug-
gest that the leucine is part of the peptide prior to ring
closure by dehydration of the threonine with N,O-Me2-
tyrosine. Does the enzyme responsible simply overcome
the steric hinderance involved, or is there another mech-
anism involving some unknown intermediate? Unfortu-
nately, very little is known about the biosynthetic path-
way from which the didemnins originate, nor the fasci-
nating chemistry that undoubtedly takes place.
3IV. MECHANISMS OF BIOLOGICAL
ACTIVITY
Recent studies appear to indicate that the natural
function of the didemnins in tunicates is as a fish re-
pellent. Fluorescent analogs of didemnin B and taman-
darin A were tested against the feeding patterns of several
species of fish, and were found to alter the predator-prey
relationship in favor of the prey12. Why would such a
function correspond with biological action against hu-
man diseases? It would appear to be due to the selective
cytotoxic potential of the compound: it is not a toxin
per se, but rather a functional repellent. This may give
it precisely the balance that is needed for medicinal uses,
with the compound being cytotoxic enough to kill vigor-
ously dividing or virally-infected cells, but (ideally) not
the host.
One of the earliest biological activities of the didemnins
A and B reported were antiviral. Rinehart noticed the
antiviral effects of didemnin on Herpes Simplex Virus 16
and other results soon followed. It was also determined
that in vitro antiviral activities against Dengue virus13,
Rift Valley fever virus14, and Rabies15 were enacted in
response to didemnin B, with didemnin A being substan-
tially less potent. It has since been determined that the
antiviral effects induced by cell treatment with didemnin
A or B are due to inhibition of RNA/DNA/protein syn-
thesis and activation of pro-apoptotic pathways.
Nearly all of the didemnins have demonstrated anti-
cancer effects. Didemnin A and B were both found to in-
hibit the growth of L1210 and P388 leukemia tumor cell
lines in vitro6. Furthermore, it has been shown that after
2 hours of treatment the halting of cell growth of L1210
cells was irreversible. This was the first clue that some-
thing besides protein synthesis was responsible for the cy-
totoxicity since apoptosis is also irreversible once certain
cellular biochemical ”checkpoints” have been passed16.
Nordidemnin B was also tested against a rat mammary
cancer line and found to alter the signaling pathways
of protein kinases involving phosphotidylinositol second
messengers, a result that also suggested an unknown pro-
cess besides (or in conjuction with) protein synthesis in-
hibition as being responsible for the cytotoxic effects17.
It is now know that the didemnins act through at least
three different mechanisms: inhibition of protein synthe-
sis, cell-cycle disruption and induction of apoptosis.
Protein synthesis has been shown to be inhibited dur-
ing peptide elongation. Didemnin B stabilizes tRNA
binding to the ribosome, thereby preventing the next
tRNA from entering and elongating the peptide18. This
mechanism of cytotoxicity is not new, as several antibi-
otics (tetracycline, kirromycin) also function in this man-
ner. Additional work provided by a clever experiment
utilizing diphtheria toxin ADP-ribosylation showed that
didemnin B forms a complex with EF-1 and the ribo-
somal subunit19. An early source also shows drastically
reduced protein synthesis as a result of the activity of
ornithine decarboxylase being terminated by didemnin
B20.
However, in addition to these extensive studies show-
ing that the didemnins inhibit protein synthesis, it was
discovered that didemnin B and dehydrodidemnin B both
induce apoptosis more rapidly than any other substance
reported21,22. Follow-up experiments also showed that
rapamycin inhibits didemnin B-induced apoptosis, defini-
tively showing that inhibition of protein synthesis is not
the sole cause of the apoptosis, but rather that apopto-
sis is activated by involvement of FK506-binding-protein-
2523.
V. CASE IN POINT: DEHYDRODIDEMNIN B
(APLIDINTM )
AplidinTM (dehydrodidemnin B), originally extracted
in 1990 from the Mediterranean tunicate Aplidum albi-
cans (and since synthesized) is of enormous pharmaceu-
tical value. This natural product has shown outstand-
ing cytotoxicity against nearly every form of solid-tumor
it has been tested against, including non-small cell lung
(one of the most deadly and aggressive manifestations
of cancer, to which there is currently no effective treat-
ment), prostate sarcoma and melanoma. Based upon cell
culture studies, rudimentary data suggests that the ther-
apeutic index of Aplidin may be high enough to meet
onco-drug standards. Once the effects of cell-cycle arrest
and apoptosis were demonstrated in vitro, and methods
for synthesizing the compound in high yield were deter-
mined, Aplidin was put on the fast-track toward becom-
ing a therapeutic drug and is currently in Phase II clinical
trials.
A. Chemical Structure
FIG. 3: Structural diagram of dehydrodidemnin B. The stan-
dard macrocycle is in place (Hip, isostatine) with a pyru-
vylproline side-chain. Interestingly, this side-chain is only
slightly different than the lactate side-chain of didemnin B,
yet the biological effects differ between the two depsipeptides
significantly.
4Dehydrodidemnin B is structurally similar to didemnin
B; instead of an N-linked lactate there is a pyruvate on
the proline side-chain. The macrocycle peptide is the
same as described earlier in this review (Hip, isostatine)
and appears essential to maintaining it’s biological activ-
ity.
It is not known why, biochemically speaking, the
pyruvyl-proline side-chain would make Aplidin a better
candidate over didemnin B in terms of both cytotoxicity
against cancer cells and also in lacking the cardiovascu-
lar side-effects which caused didemnin B to prematurely
terminate it’s Phase I trial.
B. Laboratory Synthesis
Synthesis of Dehydrodidemnin B is a simple, single
step away from didemnin A involving attachment of the
pyruvylproline to the N-Me-D-Leu site. Since this essen-
tially boils down to the synthesis of didemnin A, the focus
of the synthesis is overcoming the difficulties in forming
the macrocycle.
Several synthetic routes for the didemnins have been
published, but here we will explore the formation of the
macrocycle as ring closure of a linear precursor by way
of macrolactamization24, the following synthetic scheme
being the method of Jou et al. There are several possi-
ble points at which the ring can be closed, but in this
route the N,O-Me2-Tyr to L-Pro was selected since there
are drawbacks to the various other options (for instance,
Hip to Leu would have the tendency of decarboxylating
the -keto acid formed). Macrocyclization through this se-
lected route should not yield any obvious unwanted side
reactions.
The major difficulties to be overcome are (a) the lack of
a good nucleophile in forming the ester linkage without
affecting the carboxylic acid and (b) overcoming steric
hinderance from the crowding of peptide bonds around
a constrained ring. This synthetic route makes use of
phosphonium and uronium salt-based reagents that have
been developed for such purposes of constrained amino
acid chemistry.
The synthesis begins with the formation of ”eastern”
and ”western” segments; both segments are formed in
conjuction with the use of Boc-, Z- as amino group
protectors, Bzl and TBDMS ethers for alcohol protec-
tors, and SEM esters for the protection of the car-
boxylic acids (synthesis of these precursors can be found
in the literature24,25). Both segments are then linked
by an ester bond that is formed through hydrolysis to
give the linear precursor from which cyclization will give
didemnin A. Esterfication takes place by use of DIPCDI
and DMAP in refluxing chloroform with careful control of
temperature. This final step will give the linear macrocy-
cle precursor in 60 % yield after column chromatography.
Conversion of the linear precursor into didemnin A
takes place through deprotection of the carboxyl termi-
nus, yielding a first intermediate followed by deprotection
FIG. 4: Esterfication of the ”eastern” and ”western” segments
into a linear macrocycle precursor by oxidation with DCC or
DIPCDI in the presence of DMAP in refluxing chloroform.
Deprotection of the carboxyl group by addition of Zinc dust
in THF followed by NH4OAc. Sequential deprotection of the
amino group by 10 % Pd-C in THF. Finally, macrocyclization
in HATU, HOAt and DIEA. Each step involves additional
washes, filtrations and either silica gel or HPLC for further
purification of product.
of the amino terminus and then finally initiating macro-
cyclization by use of HATU in HOAt. Quenching with 5
M HCl-dioxane gives didemnin A in approximately 28 %
yield for this macrocyclization step (see figure 4).
Final coupling of pyruvylproline to the side-chain D-
Leu of didemnin A is done through the use of bromo-
tris-pyrrolidino-phosphonium hexafluorophosphate (Py-
BrOP), an excellent reagent for coupling N-Me amino
acids with enantiomeric specificity, giving the final prod-
uct dehydrodidemnin B in 62 % yield (see figure 5).
C. Biological Mechanism of Action, Biomedical
Applications and Clinical Trials
Dehydrodidemnin B causes cell-cycle arrest at the G1-
S checkpoint and also at G2-M by a unique mechanism22.
Inhibition of JNK and p38 MAP kinase blocked the ac-
tions of Aplidin, showing that the apoptotic program
5FIG. 5: Final reaction to give dehydrodidemnin B.
Dichloromethane, PyBrOP and DIEA added, product ex-
tracted in AcOEt. Washed in salt and potassium sulfate solu-
tions, filtered, dried and purified by silica gel chromatography.
was being triggered somewhere upstream of the caspases.
This mechanism most likely involves PKC delta, an im-
portant protein kinase that has in recent years been
shown to be an active player in apoptosis26.
It has very recently been determined that a direct
target of Aplidin is EGFR (epidermal growth factor re-
ceptor). Ironically, EGFR has been identified as a fac-
tor in promoting tumor growth. It appears that dehy-
drodidemnin B binds and activates EGFR continuously
which induces the apoptotic program27. Along similar
lines, Aplidin inhibits the secretion of VEGF (vascular
epidermal growth factor) which has been shown to kill
the leukemia cell line MOLT-4 and presumably could
have applications in suppressing angiogenesis28.
Given the initial cell culture screening and the biolog-
ical mechanism of action supported by further biochem-
ical testing, dehydrodidemnin B has been identified as
a prime candidate for biomedical application in treat-
ing cancer and autoimmune diseases. PharmaMar S.A.
(Madrid, Spain) is currently conducting Phase II clin-
ical trials of Aplidin against solid tumors and hemato-
logical malignancies (Multiple Myeloma, Hodgkin Lym-
phoma, Acute Lymphoblastic Leukemia), with approxi-
mately 400 patients having already been treated in the
USA, Canada and Europe.
VI. CONCLUSIONS
The didemnins are a fascinating family of natural prod-
ucts that have a bright future. They form a conceptual
bridge between the traditional small-molecule drugs and
the more modern drugs derived from peptides and mon-
oclonal antibodies. They have demonstrated the potent
action and versatility of a small-molecule and yet, due to
the macrocycle component, can interact more specifically
with proteins that comprise an integral part of cellular
processes.
It is hoped that the biosynthetic pathways that give
rise to the didemnins will be elucidated in the future.
Such a discovery would not only enhance our scien-
tific knowledge of biosynthetic natural product chem-
istry, but could also open the door to creating recom-
binant biosynthetic systems (such as bioengineered bac-
teria) that could be used in high throughput screening
and research of depsipeptide drugs.
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